OpenOnco · Treatment Plan

Treatment plan — Classical Hodgkin Lymphoma

PLAN-VAR-CHL-HIGHRISK-V1 · v1 · 2026-05-13

Patient

VAR-CHL-HIGHRISK · Algorithm: ALGO-CHL-1L

DiagnosisClassical Hodgkin Lymphoma

MOH / ICD-10C81.9

ICD-O-39650/3

Clinical significance of mutations (ESCAT)

Tumor-board context — the engine does not use these tiers to rank tracks

✅ Covered biomarkers (matched in KB)

Biomarker	Variant	ESCAT	Evidence	Clinical significance	Drugs	Sources
No clinically actionable variants matched in this profile.

⚠️ Not included in plan

Biomarker	Status
BIO-HBV-STATUS	BIO definition in KB; no ESCAT BMA entry — verify with clinician

Primary current-line option

Standard plan

★ DEFAULT

Indication

IND-CHL-1L-ABVD

Regimen

ABVD (Adriamycin + Bleomycin + Vinblastine + Dacarbazine), 2-6 cycles

Drugs + NSZU

Doxorubicin (DRUG-DOXORUBICIN) 25 mg/m² · IV days 1+15 of 28-day cycle · IV ✓ NSZU covered
Bleomycin (DRUG-BLEOMYCIN) 10 units/m² · IV days 1+15 of 28-day cycle · IV ✓ NSZU covered
Vinblastine (DRUG-VINBLASTINE) 6 mg/m² · IV days 1+15 of 28-day cycle · IV ✓ NSZU covered
Dacarbazine (DRUG-DACARBAZINE) 375 mg/m² · IV days 1+15 of 28-day cycle · IV ✓ NSZU covered

Supportive care

SUP-ANTIEMETIC-PREMED

Hard contraindications

CI-LVEF-LOW-FOR-ANTHRACYCLINE

Reason

Primary current-line option selected by ALGO-CHL-1L at step 1.

Other current-line alternatives (1 tracks)

Same treatment line; review when biomarker, access, contraindication, or patient-context assumptions change.

Aggressive plan

Indication

IND-CHL-1L-A-AVD

Regimen

A+AVD (Brentuximab vedotin + Adriamycin + Vinblastine + Dacarbazine), 6 cycles

Drugs + NSZU

Brentuximab vedotin (DRUG-BRENTUXIMAB-VEDOTIN) 1.2 mg/kg · IV days 1+15 of 28-day cycle × 6 · IV ✓ NSZU covered
Doxorubicin (DRUG-DOXORUBICIN) 25 mg/m² · IV days 1+15 of 28-day cycle · IV ✓ NSZU covered
Vinblastine (DRUG-VINBLASTINE) 6 mg/m² · IV days 1+15 of 28-day cycle · IV ✓ NSZU covered
Dacarbazine (DRUG-DACARBAZINE) 375 mg/m² · IV days 1+15 of 28-day cycle · IV ✓ NSZU covered

Supportive care

SUP-ANTIEMETIC-PREMED, SUP-GCSF-NEUTROPENIA

Hard contraindications

CI-LVEF-LOW-FOR-ANTHRACYCLINE, CI-BORTEZOMIB-SEVERE-NEUROPATHY, CI-HBV-NO-PROPHYLAXIS

Reason

Current-line alternative presented for HCP consideration

Pre-treatment investigations

Investigations before treatment start · critical / standard / desired · merged across tracks

ID	Name	Priority	Category	Where to order	Needed for
TEST-CBC	Complete Blood Count with Differential	Critical	lab	—	all tracks
TEST-CMP	Comprehensive Metabolic Panel	Critical	lab	—	all tracks
TEST-HBV-SEROLOGY	Hepatitis B Serology Panel (HBsAg, anti-HBc total, anti-HBs)	Critical	lab	—	all tracks
TEST-HIV-SEROLOGY	HIV Antibody/Antigen	Critical	lab	—	all tracks
TEST-LDH	Lactate Dehydrogenase	Critical	lab	—	all tracks
TEST-LFT	Liver Function Tests (ALT, AST, bilirubin, ALP, GGT, albumin)	Critical	lab	—	all tracks
TEST-LN-EXCISIONAL-BIOPSY	Excisional LN Biopsy	Critical	histology	—	all tracks
TEST-PREGNANCY	Beta-HCG	Critical	lab	—	all tracks
TEST-ECHO	Echocardiography	Standard	imaging	—	all tracks
TEST-PET-CT	FDG PET/CT (whole body)	Standard	imaging	—	all tracks

Red flags — PRO / CONTRA aggressive

PRO-AGGRESSIVE

Triggers that push toward the aggressive track

Classical Hodgkin lymphoma stage III-IV (advanced) — selects A+AVD (ECHELON-1) over ABVD if brentuximab accessibleRF-CHL-ADVANCED-STAGE

CONTRA-AGGRESSIVE

Hard contraindications to escalation

Pre-treatment LVEF <50% is an absolute contraindication to anthracycline-containing regimens (R-CHOP, Pola-R-CHP, ABVD, BV-AVD, etc.). Cardiotoxicity from doxorubicin is dose-cumulative and often irreversible; starting with already-impaired function risks acute decompensation.CI-LVEF-LOW-FOR-ANTHRACYCLINE
Severe pre-existing peripheral neuropathy is an absolute contraindication to bortezomib — therapy will likely worsen the neuropathy to a disabling and often permanent extent.CI-BORTEZOMIB-SEVERE-NEUROPATHY
Active or latent HBV without antiviral prophylaxis is an absolute contraindication to starting B-cell-depleting / immunomodulatory monoclonal antibody therapy (anti-CD20, anti-CD30 ADC, anti-CD38). Severe HBV reactivation hepatitis risk including fulminant hepatic failure.CI-HBV-NO-PROPHYLAXIS

What NOT to do

Explicit prohibitive rules, each grounded in a regimen / supportive care / contraindication entity

Standard plan (IND-CHL-1L-ABVD)

Do NOT combine with brentuximab vedotin — ABSOLUTE pulmonary toxicity contraindication.
Do NOT use G-CSF on ABVD — increases pulmonary toxicity of bleomycin.
Do NOT continue bleomycin with DLCO drop ≥25% — switch to AVD (drop bleo).
Do NOT skip baseline LVEF + DLCO + fertility preservation discussion.
Do NOT use high-flow O2 during anesthesia after bleomycin (lifetime risk).
Do NOT start without HBV screening + entecavir prophylaxis if HBsAg+ — reactivation on steroid pulse is real (also actionable if anti-HBc+ — monitor HBV-DNA q-cycle).
Do NOT interrupt ART in HIV+ patients — HIV-HL outcomes approach HIV-negative cHL with concurrent ART; avoid ritonavir-boosted PIs (vincristine interaction); PJP prophylaxis throughout.

Aggressive plan (IND-CHL-1L-A-AVD)

Do NOT combine brentuximab with bleomycin — ABSOLUTE; lethality risk.
Do NOT skip G-CSF support — neutropenia with brentuximab + anti-mitotic is higher.
Do NOT ignore pre-existing peripheral neuropathy — Grade ≥2 = absolute CI.
Do NOT prescribe without a verified funding pathway — brentuximab is not NSZU-reimbursed.
Do NOT start brentuximab without HBV screening + entecavir prophylaxis if HBsAg+ or anti-HBc+ — anti-CD30 ADC has documented HBV reactivation risk; continue ≥12 mo after last BV dose.
Do NOT interrupt ART in HIV+ — A+AVD is acceptable with ART; integrase backbone preferred (vincristine-PI interaction); PJP prophylaxis throughout.

Monitoring schedule

Monitoring schedule by treatment phase

Standard plan · MON-R-CHOP-REGIMEN

Phase	Window	Tests	Checkpoints
baseline	Within 2 weeks before cycle 1	TEST-CBC, TEST-CMP, TEST-LFT, TEST-LDH, TEST-B2-MICROGLOBULIN, TEST-HBV-SEROLOGY, TEST-HCV-ANTIBODY, TEST-HIV-SEROLOGY, TEST-PET-CT, TEST-LN-EXCISIONAL-BIOPSY, TEST-FLOW-CYTOMETRY, TEST-CD20-IHC, TEST-ECHO, TEST-PREGNANCY, TEST-BM-ASPIRATE, TEST-BM-TREPHINE	Confirm CD20+ DLBCL histology; rule out double-hit (FISH for MYC/BCL2/BCL6) Confirm HBV status + entecavir prophylaxis plan if HBsAg+ or anti-HBc+ Baseline LVEF ≥50% before doxorubicin IPI calculation documented (age, ECOG, LDH, stage, extranodal sites) CNS-IPI calculation if anatomic risk sites or composite score concerning Fertility preservation discussion (sperm banking / oocyte cryo) for childbearing-age
on_treatment	Day 1 of every 21-day cycle	TEST-CBC, TEST-CMP, TEST-LFT	ANC ≥1500 + platelets ≥100K before each cycle (delay or G-CSF if not) Neuropathy grade documented (CTCAE) — vincristine modification if ≥2 LVEF re-check after cumulative doxorubicin ~300 mg/m²
interim_response_assessment	After cycles 2-4 (interim PET-CT)	TEST-PET-CT, TEST-LDH	Lugano response criteria + Deauville score If Deauville 4-5 with mass progression → consider salvage or trial
end_of_treatment	After cycle 6 (within 6-8 weeks)	TEST-PET-CT, TEST-CBC, TEST-CMP, TEST-LDH	Confirm CR vs PR vs SD vs PD by Lugano/Deauville Begin survivorship plan: cardiac surveillance schedule, vaccination catch-up, second-cancer screening
follow_up_short	Every 3 months × 2 years post-treatment	TEST-CBC, TEST-CMP, TEST-LFT, TEST-LDH	Surveillance for relapse (~40% relapse risk by 2 years overall) HBV reactivation monitoring continues for 12 months post anti-CD20
follow_up_long	Every 6 months years 3-5, then annually	TEST-CBC, TEST-LFT, TEST-ECHO	Late cardiomyopathy screening (LVEF) annually if cumulative dox >300 Annual second-malignancy screening (skin, breast, etc. age-appropriate)

Timeline

Treatment timeline — derived from regimen + monitoring schedule

Standard plan

Baseline

Within 2 weeks before cycle 1

Induction · ABVD (Adriamycin + Bleomycin + Vinblastine + Dacarbazine), 2-6 cycles

28-day cycles × 2-4 (early-stage + ISRT) OR 6 (advanced); response-adapted per interim PET-CT Deauville

Response assessment

After cycles 2-4 (interim PET-CT)

Follow-up

Every 3 months × 2 years post-treatment

Aggressive plan

Baseline

Within 2 weeks before cycle 1

Induction · A+AVD (Brentuximab vedotin + Adriamycin + Vinblastine + Dacarbazine), 6 cycles

28-day cycles × 6

Response assessment

After cycles 2-4 (interim PET-CT)

Follow-up

Every 3 months × 2 years post-treatment

MDT brief

Discussion questions (2, 1 blocking)

BLOCKING OQ-CD20-CONFIRMATION
Is CD20+ status confirmed by histology (IHC)? Without CD20+, rituximab/obinutuzumab are not indicated.
Anti-CD20 therapy is the backbone of most lines of treatment; absence of CD20 expression fully changes the regimen.
→ pathologist
OQ-STAGING-COMPLETE
Has complete staging been done (Lugano + PET/CT or CT)?
Prognosis and track selection depend on stage and tumor burden.
→ radiologist

MDT talk tree (4 steps)

#	Owner	Topic	Action
1	pathologist	Pathology confirmation BLOCKING	Is CD20+ status confirmed by histology (IHC)? Without CD20+, rituximab/obinutuzumab are not indicated.
2	radiologist	Staging / disease burden	Has complete staging been done (Lugano + PET/CT or CT)?
3	hematologist	Specialist review	Lymphoma diagnosis — leading specialty for treatment management.
4	clinical_pharmacist	Specialist review	Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.

Skills (required) — mandatory virtual specialists (1)

Hematologist / oncohematologist required
Lymphoma diagnosis — leading specialty for treatment management.

Skills (recommended) — for consideration (3)

Clinical pharmacist recommended
Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.
Pathologist (general) recommended
Confirm lymphoma histology + assess transformation risk (DLBCL/Richter).
Owns: OQ-CD20-CONFIRMATION
Radiologist recommended
Imaging findings present — radiologist needed for staging/restaging.
Owns: OQ-STAGING-COMPLETE

Data quality

Incomplete for MDT sign-off. MDT sign-off is incomplete until critical clinical data gaps are resolved.

Biomarker coverage: 2/2 known (100%), 0 missing, 0 default-track gaps
Missing critical: cd20_ihc_status, lugano_stage
Missing recommended: fib4_index, pet_ct_date
Unevaluated RedFlags: RF-ACTIVE-AUTOIMMUNE-DISEASE-ICI-RISK, RF-CHL-ADVANCED-STAGE, RF-CHL-FRAILTY-AGE, RF-CHL-INFECTION-SCREENING, RF-CHL-ORGAN-DYSFUNCTION, RF-CHL-TRANSFORMATION-PROGRESSION

Missing data for doctor action

Priority	Clinical item	Owner	Why it matters	Next action	Blocks
CRITICAL	CD20 IHC status `cd20_ihc_status`	pathologist	Confirms CD20-directed therapy is biologically appropriate.	Verify CD20 IHC result, specimen, method, and report date.	-
CRITICAL	Lugano stage `lugano_stage`	radiologist	Defines lymphoma extent and supports tumor-burden and response-assessment decisions.	Document Lugano stage from PET/CT or contrast CT staging.	-
RECOMMENDED	FIB-4 liver fibrosis index `fib4_index`	infectious_disease_hepatology	Screens hepatic fibrosis risk before hepatotoxic therapy or antiviral coordination.	Calculate FIB-4 from age, AST, ALT, and platelet count.	-
RECOMMENDED	PET/CT date `pet_ct_date`	radiologist	Shows whether baseline staging is recent enough for treatment planning and later response comparison.	Document baseline PET/CT date or explain alternative staging modality.	-

Technical MDT skill metadata (4/16 activated in this plan)

All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).

Specialist	skill_id	Version	Last reviewed	Domain
Cellular therapy specialist (CAR-T)	`cellular_therapy_specialist`	v0.1.0	2026-04-25	cellular_therapy
Clinical pharmacist	`clinical_pharmacist`	v0.1.0	2026-04-25	clinical_pharmacy
Hematologist / oncohematologist	`hematologist`	v0.1.0	2026-04-25	hematology_oncology
Hematopathologist (lymphoma / leukemia / myeloma)	`hematopathologist`	v0.1.0	2026-04-25	hematopathology
Infectious disease / hepatology	`infectious_disease_hepatology`	v0.1.0	2026-04-25	infectious_diseases
Medical oncologist (solid-tumor chemotherapist)	`medical_oncologist`	v0.1.0	2026-04-25	solid_oncology
Molecular geneticist / molecular oncologist	`molecular_geneticist`	v0.1.0	2026-04-25	molecular_oncology
Palliative care	`palliative_care`	v0.1.0	2026-04-25	palliative_care
Pathologist (general)	`pathologist`	v0.1.0	2026-04-25	pathology
Primary care / family physician	`primary_care`	v0.1.0	2026-04-25	primary_care
Psycho-oncologist	`psychologist`	v0.1.0	2026-04-25	psychosocial
Radiation oncologist	`radiation_oncologist`	v0.1.0	2026-04-25	radiation_oncology
Radiologist	`radiologist`	v0.1.0	2026-04-25	diagnostic_imaging
Social worker / case manager	`social_worker_case_manager`	v0.1.0	2026-04-25	psychosocial
Surgical oncologist	`surgical_oncologist`	v0.1.0	2026-04-25	surgical_oncology
Transplant specialist (BMT)	`transplant_specialist`	v0.1.0	2026-04-25	cellular_therapy

Sources cited

SRC-ECHELON-1-CONNORS-2018: Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma (2018)
SRC-NCCN-BCELL-2025: NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas (v.2.2025)

Experimental options (clinical trials)

Third plan track — open-enrollment trials from ClinicalTrials.gov. Render-time metadata; engine selection is not affected by this block (CHARTER §8.3). Last synced: 2026-05-13.

NCT	Title	Phase	Status	Sponsor	UA	Signals
NCT04510636	Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma	PHASE2	RECRUITING	University Health Network, Toronto	—	Small N (<50) Surrogate endpoint only Single country
NCT06796517	Immunotherapy in Lymphoma	N/A	RECRUITING	Sung-Soo Park	—	Single country
NCT06822855	Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma	N/A	RECRUITING	Azienda USL Reggio Emilia - IRCCS	—	Single country
NCT04288726	Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas	PHASE1	RECRUITING	Baylor College of Medicine	—	Phase 1 only Small N (<50) Single country
NCT05705531	A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma	N/A	RECRUITING	Children's Oncology Group	—	—
NCT04561206	Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma	PHASE2	RECRUITING	City of Hope Medical Center	—	Small N (<50) Surrogate endpoint only Single country
NCT07356882	European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma	N/A	RECRUITING	Assistance Publique - Hôpitaux de Paris	—	Single country
NCT05404945	Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above	PHASE2	RECRUITING	University of Virginia	—	Small N (<50) Single country
NCT05896046	SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma	PHASE1 / PHASE2	RECRUITING	Chinese PLA General Hospital	—	Surrogate endpoint only Single country
NCT06848569	Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study	PHASE2	RECRUITING	Sun Yat-sen University	—	Single country

Verify recruitment status directly with the trial site. ctgov data can lag behind current UA-site status.

Option availability in Ukraine

Per-track UA registration · NSZU · cost · access pathway. Render-time metadata; engine selection does not depend on these fields (CHARTER §8.3).

Option	UA registration	NSZU	Cost orientation	Access pathway
Standard plan ABVD (Adriamycin + Bleomycin + Vinblastine + Dacarbazine), 2-6 cycles (REG-ABVD)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Aggressive plan A+AVD (Brentuximab vedotin + Adriamycin + Vinblastine + Dacarbazine), 6 cycles (REG-A-AVD)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Trial · NCT04510636 Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06796517 Immunotherapy in Lymphoma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06822855 Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT04288726 Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT05705531 A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT04561206 Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07356882 European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT05404945 Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT05896046 SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06848569 Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor

Cost information is orientation. Verify with a specific pharmacy / foundation / trial site. Status updated: 2026-05-13.

plan_id: PLAN-VAR-CHL-HIGHRISK-V1 | version: 1 | generated: 2026-05-13T10:01:51.823828+00:00

Per FDA non-device CDS positioning (CHARTER §15): Outpatient oncology treatment planning to support tumor-board discussion. Not a medical device; not for autonomous clinical decision-making.

Per FDA non-device CDS positioning (CHARTER §15): Both treatment options below are presented for review. The engine's selection of a 'recommended' default does not constitute a clinical decision. Final treatment selection requires HCP judgment incorporating information not available to the system.

This document is an informational resource supporting tumor-board discussion (per CHARTER §11). It is not a system that makes clinical decisions. Every recommendation must be verified by the treating physician.